Market Cap 155.92B
Revenue (ttm) 28.75B
Net Income (ttm) 480.00M
EPS (ttm) N/A
PE Ratio 15.29
Forward PE 15.33
Profit Margin 1.67%
Debt to Equity Ratio 1.16
Volume 2,073,800
Avg Vol 7,254,968
Day's Range N/A - N/A
Shares Out 1.24B
Stochastic %K 71%
Beta 0.32
Analysts Strong Sell
Price Target $133.74

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis....

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 574 3000
Fax: 650 578 9264
Address:
333 Lakeside Drive, Foster City, United States
RaindropRhythm
RaindropRhythm Dec. 26 at 5:28 PM
$GILD Capital is flowing toward execution strength rather than speculative optionality. Capital allocation choices will reveal true priorities. Overextension would degrade optionality during downturns. Without validation, volatility will remain persistent.
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 4:44 PM
🔎 $GILD Options Scan Update (10:44 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
IN0V8
IN0V8 Dec. 26 at 4:31 PM
$GILD Opportunity Truist Securities assumes coverage with buy rating; target $140
0 · Reply
prismmarketview
prismmarketview Dec. 26 at 3:34 PM
Gilead (NASDAQ: $GILD)is bolstering its precision oncology pipeline by acquiring Repare’s Phase 1 Polθ ATPase inhibitor RP‑3467 for up to $30 million in cash, adding a synthetic‑lethality DNA‑repair asset being tested alone and with PARP inhibitor olaparib in BRCA‑mutated and other genomically unstable cancers. https://prismmarketview.com/gilead-sciences-acquires-repares-rp-3467-to-expand-precision-oncology-pipeline/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 6:06 AM
Enter: $GILD Calls Strike Price: $130 Expiry Date: JAN 16 2026 Buy in Price: $1.66 - $1.78 Sell Price: $3.00 Profit : +81% (Turn every $1 into $1.81) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:25 PM
Actionable Trade Alert for $GILD: Market Context: $GILD is currently trading at $125.67, showing a strong position relative to its recent price action. The RSI at 58.16 indicates bullish momentum, suggesting potential for further upward movement. The stock is above both the 30-day MA (123.79) and the 50-day MA (122.57), indicating a positive trend. Directional Bias: The recent high of $128.7 suggests resistance, while the low of $108.46 provides a solid support base. Given the current RSI and moving averages, we anticipate a bullish continuation. Trade Plan: - Suggested Entry: $126.00 - Stop Loss: $121.00 (around 4% below entry) - Take Profit Targets: 1. $128.00 (1st Target - 1.6% ROI) 2. $130.00 (2nd Target - 3.2% ROI) 3. $147.00 (3rd Target - 16.9% ROI) This plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
1iquid
1iquid Dec. 25 at 9:04 AM
💎 Liquid® Live Actionable Trade Asset: $GILD Contracts: $GILD January 15, 2027 $130 Calls Scale in: $11.82- $14.45 Scale out: $45.98-$78.82 Profit Potential : 300% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 8:22 PM
Enter: $GILD Calls Strike Price: $130 Expiry Date: JAN 16 2026 Buy in Price: $1.30 - $1.37 Sell Price: $1.99 Profit : +53% (Turn every $1 into $1.53) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
topstockalerts
topstockalerts Dec. 24 at 8:04 PM
Repare Therapeutics announced a definitive asset purchase agreement with Gilead Sciences under which Gilead will acquire Repare’s Polθ ATPase inhibitor, RP-3467. Repare will receive up to $30 million in total consideration, including a $25 million upfront payment and up to $5 million tied to the completion of specific technology transfer activities. Management described the deal as the most significant of Repare’s three portfolio transactions this year, highlighting the strategic fit between RP-3467 and Gilead’s oncology R&D capabilities. The transaction follows Repare’s recent agreement to be acquired by XenoTherapeutics and Xeno Acquisition Corp. The upfront payment from Gilead has boosted Repare’s cash balance, increasing the estimated cash payout to shareholders in the Xeno acquisition to about $2.20 per share, up from prior expectations. $RPTX $GILD
0 · Reply
Mervolo
Mervolo Dec. 24 at 6:12 PM
$LAZR oh man, guess we shoulda bought more at ,13 :( glad to see the movement but sad we didn t load more boat today $RPTX hoping ah or fri will bring more ppl. Thouhht $GILD tying in would cause more of a rally hut if we alreadya tarted celebrating, pretty sure wally boys ready to call it a day and get to that offica partayyyyy $MWG nice little bounce there. Again, offered some decent scalps but, guess that s why they restrixt these to call ins. Oh wells Looking to rptx for ah maybe somethjng since lazr gonna go quiet at bell. Trying to rearrange the studio. Let s see if we can t get some new pieces rollin thise week
0 · Reply
Latest News on GILD
Gilead Sciences to Present at Upcoming Investor Conference

Dec 22, 2025, 4:05 PM EST - 4 days ago

Gilead Sciences to Present at Upcoming Investor Conference


Gilead, Arcus scrap late-stage trial of cancer drug combo

Dec 12, 2025, 8:36 AM EST - 14 days ago

Gilead, Arcus scrap late-stage trial of cancer drug combo


Gilead Sciences: About To Break Out

Nov 25, 2025, 6:17 AM EST - 4 weeks ago

Gilead Sciences: About To Break Out


Can Gilead Stock Outrun Regeneron In The Next Rally?

Nov 13, 2025, 9:00 AM EST - 6 weeks ago

Can Gilead Stock Outrun Regeneron In The Next Rally?


Gilead Provides Update on Phase 3 ASCENT-07 Study

Nov 7, 2025, 8:30 AM EST - 7 weeks ago

Gilead Provides Update on Phase 3 ASCENT-07 Study


Gilead Sciences to Present at Upcoming Investor Conferences

Nov 4, 2025, 4:05 PM EST - 7 weeks ago

Gilead Sciences to Present at Upcoming Investor Conferences


Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 8:56 PM EDT - 2 months ago

Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript


Gilead Sciences Announces Third Quarter 2025 Financial Results

Oct 30, 2025, 4:02 PM EDT - 2 months ago

Gilead Sciences Announces Third Quarter 2025 Financial Results


What To Expect From Gilead In Q3 2025

Oct 24, 2025, 10:56 AM EDT - 2 months ago

What To Expect From Gilead In Q3 2025


Final Trade: F, HAL, MA, GILD

Oct 21, 2025, 6:21 PM EDT - 2 months ago

Final Trade: F, HAL, MA, GILD

F HAL MA


Gilead's Trodelvy cuts breast cancer risk by 38% in trial

Oct 19, 2025, 2:33 AM EDT - 2 months ago

Gilead's Trodelvy cuts breast cancer risk by 38% in trial


RaindropRhythm
RaindropRhythm Dec. 26 at 5:28 PM
$GILD Capital is flowing toward execution strength rather than speculative optionality. Capital allocation choices will reveal true priorities. Overextension would degrade optionality during downturns. Without validation, volatility will remain persistent.
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 4:44 PM
🔎 $GILD Options Scan Update (10:44 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
IN0V8
IN0V8 Dec. 26 at 4:31 PM
$GILD Opportunity Truist Securities assumes coverage with buy rating; target $140
0 · Reply
prismmarketview
prismmarketview Dec. 26 at 3:34 PM
Gilead (NASDAQ: $GILD)is bolstering its precision oncology pipeline by acquiring Repare’s Phase 1 Polθ ATPase inhibitor RP‑3467 for up to $30 million in cash, adding a synthetic‑lethality DNA‑repair asset being tested alone and with PARP inhibitor olaparib in BRCA‑mutated and other genomically unstable cancers. https://prismmarketview.com/gilead-sciences-acquires-repares-rp-3467-to-expand-precision-oncology-pipeline/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 6:06 AM
Enter: $GILD Calls Strike Price: $130 Expiry Date: JAN 16 2026 Buy in Price: $1.66 - $1.78 Sell Price: $3.00 Profit : +81% (Turn every $1 into $1.81) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:25 PM
Actionable Trade Alert for $GILD: Market Context: $GILD is currently trading at $125.67, showing a strong position relative to its recent price action. The RSI at 58.16 indicates bullish momentum, suggesting potential for further upward movement. The stock is above both the 30-day MA (123.79) and the 50-day MA (122.57), indicating a positive trend. Directional Bias: The recent high of $128.7 suggests resistance, while the low of $108.46 provides a solid support base. Given the current RSI and moving averages, we anticipate a bullish continuation. Trade Plan: - Suggested Entry: $126.00 - Stop Loss: $121.00 (around 4% below entry) - Take Profit Targets: 1. $128.00 (1st Target - 1.6% ROI) 2. $130.00 (2nd Target - 3.2% ROI) 3. $147.00 (3rd Target - 16.9% ROI) This plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
1iquid
1iquid Dec. 25 at 9:04 AM
💎 Liquid® Live Actionable Trade Asset: $GILD Contracts: $GILD January 15, 2027 $130 Calls Scale in: $11.82- $14.45 Scale out: $45.98-$78.82 Profit Potential : 300% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 8:22 PM
Enter: $GILD Calls Strike Price: $130 Expiry Date: JAN 16 2026 Buy in Price: $1.30 - $1.37 Sell Price: $1.99 Profit : +53% (Turn every $1 into $1.53) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
topstockalerts
topstockalerts Dec. 24 at 8:04 PM
Repare Therapeutics announced a definitive asset purchase agreement with Gilead Sciences under which Gilead will acquire Repare’s Polθ ATPase inhibitor, RP-3467. Repare will receive up to $30 million in total consideration, including a $25 million upfront payment and up to $5 million tied to the completion of specific technology transfer activities. Management described the deal as the most significant of Repare’s three portfolio transactions this year, highlighting the strategic fit between RP-3467 and Gilead’s oncology R&D capabilities. The transaction follows Repare’s recent agreement to be acquired by XenoTherapeutics and Xeno Acquisition Corp. The upfront payment from Gilead has boosted Repare’s cash balance, increasing the estimated cash payout to shareholders in the Xeno acquisition to about $2.20 per share, up from prior expectations. $RPTX $GILD
0 · Reply
Mervolo
Mervolo Dec. 24 at 6:12 PM
$LAZR oh man, guess we shoulda bought more at ,13 :( glad to see the movement but sad we didn t load more boat today $RPTX hoping ah or fri will bring more ppl. Thouhht $GILD tying in would cause more of a rally hut if we alreadya tarted celebrating, pretty sure wally boys ready to call it a day and get to that offica partayyyyy $MWG nice little bounce there. Again, offered some decent scalps but, guess that s why they restrixt these to call ins. Oh wells Looking to rptx for ah maybe somethjng since lazr gonna go quiet at bell. Trying to rearrange the studio. Let s see if we can t get some new pieces rollin thise week
0 · Reply
Neahrain8
Neahrain8 Dec. 24 at 4:56 PM
$PDD $SPGI $COF $GILD $SONY I also know it.
0 · Reply
DownVotedDiv
DownVotedDiv Dec. 24 at 3:52 PM
$GILD Sustained appreciation requires alignment between technological leadership and commercial adoption, with outcomes shaped by timing and discipline. Outcomes hinge on delivery, not scale.
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Dec. 24 at 3:42 PM
$KYTX all big players in the cell therapy space like $AZN $GILD $AMGN $VRTX will have noticed these life changing results and have their M&A analysts running the numbers up and down right now to evaluate next steps in 2026. A merry Christmas to everyone here. Let's do some good with our investments here on this holy day 🎄🎅💲 https://kyvernatx.com/education-events/educational-videos/
1 · Reply
Noobnr1
Noobnr1 Dec. 24 at 3:26 PM
$OMER and $DVAX for the Christmas gifts 🤩 $PHARM for new year? $GILD $PFE for 2026🙏
0 · Reply
LimitTorch_1680
LimitTorch_1680 Dec. 24 at 2:12 PM
$GILD slow grind higher trend confirmation comes with sustained volume
0 · Reply
EchoAnalysis
EchoAnalysis Dec. 24 at 1:46 PM
Gilead Sciences acquires Repare Therapeutics' cancer asset RP-3467 for $30 million to advance oncology research and development. $RPTX $GILD
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 24 at 12:51 PM
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug $RPTX $GILD https://stocktwits.com/news/equity/markets/rptx-stock-soars-after-gilead-agrees-to-acquire-repare-investigational-cancer-treatment/cLesuB8REvI
0 · Reply
notreload_ai
notreload_ai Dec. 24 at 12:47 PM
$GILD purchases RP-3467, a promising cancer treatment targeting BRCA mutations, from $RPTX in a deal worth up to $30 million. https://notreload.xyz/gilead-buys-repare-rp-3467-cancer-drug/
0 · Reply
Reanimated666
Reanimated666 Dec. 23 at 6:34 PM
$GILD Dodge the Jabs and counter
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 6:23 PM
Big move in biotech ⚡ $GILD just locked in Assembly Bio’s herpes programs — this matters. Gilead exercised its option to license ASMB’s HSV programs, advancing long-acting candidates ABI-1179 and ABI-5366 for recurrent genital herpes — a clear commitment to pushing these assets forward. See the full breakdown here 👉 https://www.zacks.com/stock/news/2808054/gild-exercises-option-to-license-assembly-bios-herpes-programs?cid=sm-stocktwits-2-2808054-teaser-26071&ADID=SYND_STOCKTWITS_TWEET_2_2808054_TEASER_26071
0 · Reply
Johnny_Lever
Johnny_Lever Dec. 23 at 5:52 PM
$GILD Continuing to move higher.
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 5:23 PM
$GILD takes a bold step in the antiviral race! 💊 Gilead just licensed Assembly Bio’s herpes inhibitor programs in a 12-year partnership, aiming to fill a treatment gap with ABI-5366 & ABI-1179, which showed promising results in a phase Ib study! 🚀 See why this could be a game-changer for Gilead 👉 https://www.zacks.com/stock/news/2808054/gild-exercises-option-to-license-assembly-bios-herpes-programs?cid=sm-stocktwits-2-2808054-body-26068&ADID=SYND_STOCKTWITS_TWEET_2_2808054_BODY_26068
0 · Reply